

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

JANUARY 22, 2004

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

FLORIDA	333-100568	59-3410522
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12085 RESEARCH DRIVE
ALACHUA, FLORIDA 32615

(Address of principal executive offices including zip code)

(386) 418-4018

Registrant's telephone number, including area code

NONE

(Former name or former address, if changed since last report.)

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

EXHIBIT NO.	DESCRIPTION
-------------	-------------

99.1	Press Release
------	---------------

ITEM 9. REGULATION FD DISCLOSURE

Oragenics, Inc. announces today that its common shares have been accepted for quotation on the OTC Bulletin Board under the stock symbol "OGEN."

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly

authorized on this 22nd day of January, 2004.

ORAGENICS, INC.
(REGISTRANT)

BY: /s/ Mento A. Soponis

Mento A. Soponis
President, Principal
Executive Officer and a
member of the Board of
Directors.

Contact:
Mento A. "Chuck" Sponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

FOR IMMEDIATE RELEASE

ORAGENICS, INC. BEGINS TRADING ON THE OTC BULLETIN BOARD REGISTRY.

ALACHUA, FL (JANUARY 22, 2004) - Oragenics, Inc. (TSX-V:ORA.U), a publicly held biotechnology company, today announced that its common shares have been accepted for quotation on the OTC Bulletin Board, effective immediately. Oragenics' stock symbol is "OGEN."

Mento "Chuck" Sponis, president and chief executive officer of Oragenics said, "This listing is an important corporate milestone for Oragenics. Our shareholders should benefit from this event through more efficient trading and, potentially, increased liquidity in Oragenics' stock."

Oragenics, Inc. is an emerging biotechnology research and development company that began operations in 1999. Located in Alachua, Florida at the University of Florida's Sid Martin Biotechnology Development Incubator, Oragenics is developing three new healthcare products. The most advanced product is an oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The second product in pre-clinical development is a broad-spectrum antibiotic. Oragenics is also developing a probiotic product to maintain oral health. For more information about Oragenics, please consult the Company's website at www.oragenics.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF

1995: This release includes forward-looking statements which reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions which do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic, and probiotic product for oral health; (2) the ability to obtain substantial additional funding; (3) the ability to develop and commercialize products before competitors; and (4) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

###

12085 Research Drive o Alachua, FL 32615 o tel: 386.418.4018
o fax: 386.462.0875 o oragen@biotech.ufl.org